Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA; Tej Kohli Cornea Institute, L.V. Prasad Eye Institute, Hyderabad, India.
Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA; Tufts University School of Medicine, Boston, Massachusetts, USA.
Am J Ophthalmol. 2019 Dec;208:331-341. doi: 10.1016/j.ajo.2019.07.006. Epub 2019 Jul 19.
To describe the long-term effect of a treatment protocol for ocular involvement in acute Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), including focused ocular examination and pathology-appropriate use of lubrication, topical corticosteroids, topical antibiotics, and amniotic membrane transplantation (AMT).
Retrospective, comparative case series.
A total of 48 patients (96 eyes) were included in this study. Nine of 48 patients (18 eyes) had acute SJS/TEN from 2000 to 2007 and did not receive protocol care (Group I). Thirty-nine of 48 patients (78 eyes) had acute SJS/TEN from 2008 to 2017 and received protocol care (Group II). The main outcome measures were best-corrected visual acuity (BCVA) at final follow-up visit and incidence of complications in the chronic phase.
No eyes in Group I received AMT for SJS/TEN, compared to 87% of qualifying eyes in Group II (P < .0001) There was a significant difference in the proportion of eyes with BCVA ≥20/40 at last follow-up between Group I and Group II (33% vs 92%, P < .001). The proportion of eyes with vision-threatening complications in the chronic phase was significantly higher in Group I versus Group II (67% vs 17%, P = .002), with most complications occurring in the first 2 years after disease onset in both groups.
A specific protocol for acute ocular care in SJS/TEN, including aggressive use of AMT, was highly successful in reducing corneal blindness and severe vision-threatening complications of the disorder.
描述急性 Stevens-Johnson 综合征/中毒性表皮坏死松解症(SJS/TEN)眼部病变治疗方案的长期疗效,包括有针对性的眼部检查和适当应用润滑、局部皮质类固醇、局部抗生素以及羊膜移植(AMT)。
回顾性、对照病例系列。
本研究共纳入 48 例患者(96 只眼)。9 例(18 只眼)患者的急性 SJS/TEN 发生于 2000 年至 2007 年,未接受方案治疗(I 组);39 例(78 只眼)患者的急性 SJS/TEN 发生于 2008 年至 2017 年,接受了方案治疗(II 组)。主要观察指标为末次随访时最佳矫正视力(BCVA)和慢性期并发症发生率。
I 组中无一例患者因 SJS/TEN 接受 AMT,而 II 组中 87%符合条件的眼接受了 AMT(P <.0001)。两组末次随访时 BCVA ≥20/40 的眼比例有显著差异(33%比 92%,P <.001)。I 组慢性期有视力威胁性并发症的眼比例明显高于 II 组(67%比 17%,P =.002),两组大多数并发症均发生在疾病发病后的前 2 年。
SJS/TEN 急性眼部治疗的特定方案,包括积极应用 AMT,在降低角膜盲和严重视力威胁性并发症方面非常成功。